Results 21 to 30 of about 830,673 (331)

Collagenolytic Enterococcus faecalis induces DDR1 signaling, proliferation and altered immune infiltrate in colorectal peritoneal metastases [PDF]

Surgery Open Science
Background: Intratumoral pathogens are an emerging paradigm in metastatic colorectal cancer (CRC). Overgrowth of Enterococcus faecalis was shown to promote local recurrence in the colon, in a fashion dependent on collagenolytic virulence factors.
Richard Jacobson, Sean Dineen, John Mullinax, Ryan Martin, Sidharth Mishra, Michelle Maurin, Ramani Soundararajan, Timothy Nywening, Andreas Karachristos, Hariom Yadav, Timothy Yeatman, Jason Fleming   +11 more
doaj   +2 more sources

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.

The Lancet Oncology, 2021
BACKGROUND The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery has been associated with encouraging survival results in some patients with colorectal peritoneal metastases who were eligible for complete macroscopic ...
F. Quénet, D. Elias, L. Roca, D. Goéré, L. Ghouti, M. Pocard, O. Facy, C. Arvieux, G. Lorimier, D. Pezet, F. Marchal, V. Loi, P. Meeus, B. Juzyna, H. de Forges, J. Paineau, O. Glehen   +16 more
semanticscholar   +1 more source

Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial

Journal of Clinical Oncology, 2023
PURPOSE In patients with peritoneal metastasis (PM) from gastric cancer (GC), chemotherapy is the treatment of choice. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are still being debated. This randomized, controlled,
B. Rau, Hau-Ke Lang, A. Koenigsrainer, Ines Gockel, H. Rau, H. Seeliger, C. Lerchenmueller, D. Reim, R. Wahba, Martin K Angele, S. Heeg, Tobias Keck, A. Weimann, S. Topp, P. Piso, A. Brandl, Silke Schuele, Peter Jo, J. Pratschke, S. Wegel, A. Rehders, N. Moosmann, J. Gaedcke, Volker Heinemann, E. Trips, M. Loeffler, P. Schlag, P. Thuss-Patience   +27 more
semanticscholar   +1 more source

Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity

British Journal of Cancer, 2022
Peritoneal metastases (PM) in colorectal cancer (CRC) are associated with therapy resistance and poor survival. Oxaliplatin monotherapy is widely applied in the intraperitoneal treatment of PM, but fails to yield clinical benefit.
J. Laoukili, A. Constantinides, E. Wassenaar, S. Elias, Daniëlle A. E. Raats, S. V. van Schelven, Jonathan van Wettum, R. Volckmann, J. Koster, A. Huitema, S. Nienhuijs, I. D. de Hingh, R. Wiezer, H. V. van Grevenstein, I. B. Borel Rinkes, D. Boerma, O. Kranenburg   +16 more
semanticscholar   +1 more source

Treatment of peritoneal metastases from colorectal cancer [PDF]

, 2023
Ten per cent of patients with colorectal cancer will develop peritoneal metastases. These metastases are known to have a lesser response to systemic chemotherapy than liver- and lung metastases.
Verwaal, Victor Jilbert, Clausen Nielsen, Jesper   +1 more
core   +4 more sources

GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases

BMC Cancer, 2022
Background The French PRODIGE 7 trial, published on January 2021, has raised doubts about the specific survival benefit provided by HIPEC with oxaliplatin 460 mg/m 2 (30 minutes) for the treatment of peritoneal metastases from colorectal cancer. However,
Fernando Magno Quintão Pereira, A. Serrano, I. Manzanedo, E. Pérez-Viejo, S. González-Moreno, L. González-Bayón, Á. Arjona‐Sánchez, J. Torres, I. Ramos, M. Barrios, P. Cascales, R. Morales, E. Boldo, A. García-Fadrique, X. Arteaga, A. Gutiérrez-Calvo, S. Sánchez-García, E. Asensio, Cesar P. Ramírez, M. Artiles, J. Vaqué, Pedro A. Parra, P. Villarejo, Cristóbal Muñoz-Casares, E. Turienzo, A. Calero, I. J. Torrejimeno, I. Prieto, J. Galindo, Vicente Borrego, M. Marcello, C. Rihuete, J. Carrasco, L. Gómez-Quiles   +33 more
semanticscholar   +1 more source

A proposed new Japanese classification of synchronous peritoneal metastases from colorectal cancer: A multi‐institutional, prospective, observational study conducted by the Japanese Society for Cancer of the Colon and Rectum

Annals of Gastroenterological Surgery, 2023
Aim To establish a new Japanese classification of synchronous peritoneal metastases from colorectal cancer. Methods This multi‐institutional, prospective, observational study enrolled patients who underwent surgery for colorectal cancer with synchronous ...
Hirotoshi Kobayashi, Kenjiro Kotake, Masayasu Kawasaki, Yukihide Kanemitsu, Yusuke Kinugasa, Hideki Ueno, Kotaro Maeda, Takeshi Suto, Michio Itabashi, Kimihiko Funahashi, Heita Ozawa, Fumikazu Koyama, Shingo Noura, Hideyuki Ishida, Masayuki Ohue, Tomomichi Kiyomatsu, Soichiro Ishihara, Keiji Koda, Hideo Baba, Kenji Kawada, Yojiro Hashiguchi, Takanori Goi, Yuji Toiyama, Naohiro Tomita, Eiji Sunami, Yoshito Akagi, Jun Watanabe, Kenichi Hakamada, Goro Nakayama, Kenichi Sugihara, Yoichi Ajioka   +30 more
doaj   +1 more source

Multimodal CEA-targeted fluorescence and radioguided cytoreductive surgery for peritoneal metastases of colorectal origin

Nature Communications, 2022
In patients with colorectal peritoneal metastases scheduled for cytoreductive surgery, accurate preoperative estimation of tumor burden and subsequent intraoperative detection of all tumor deposits remains challenging.
J. D. de Gooyer, F. M. Elekonawo, A. Bremers, O. Boerman, E. Aarntzen, P. D. de Reuver, I. Nagtegaal, M. Rijpkema, J. D. de Wilt   +8 more
semanticscholar   +1 more source

Prognostic characteristics and clinical response to immunotherapy targeting programmed cell death 1 for patients with advanced gastric cancer with liver metastases

Frontiers in Immunology, 2022
BackgroundThe specific efficacy of immunotherapy for patients with liver metastases of gastric cancer is unclear. This study set out to explore the treatment response and related prognostic factors for patients with liver metastases of gastric cancer ...
Huayuan Liang, Zhiwei Li, Zhicheng Huang, Chaorui Wu, Yaopeng Qiu, Yanrui Liang, Xinhua Chen, Fengping Li, Zhou Xu, Guoxin Li, Hao Liu, Liying Zhao   +11 more
doaj   +1 more source

Decellularized extracellular matrix as scaffold for cancer organoid cultures of colorectal peritoneal metastases

Journal of Molecular Cell Biology, 2022
Peritoneal metastases (PM) from colorectal cancer (CRC) are associated with poor survival. The extracellular matrix (ECM) plays a fundamental role in modulating the homing of CRC metastases to the peritoneum.
L. Varinelli, M. Guaglio, S. Brich, Susanna Zanutto, A. Belfiore, F. Zanardi, F. Iannelli, A. Oldani, Elisa Costa, M. Chighizola, Ewelina Lorenc, S. Minardi, Stefano Fortuzzi, Martina Filugelli, G. Garzone, F. Pisati, M. Vecchi, G. Pruneri, S. Kusamura, D. Baratti, L. Cattaneo, D. Parazzoli, A. Podestà, M. Milione, M. Deraco, M. Pierotti, M. Gariboldi   +26 more
semanticscholar   +1 more source